23 Hrs
Source:
اليوم السابع
_1777352142843_145525226.png&w=48&q=75){kind=small}
FDA Approves New Pancreatic Cancer Pill
The U.S. Food and Drug Administration (FDA) has approved a new treatment for metastatic pancreatic cancer, marking an important development in therapeutic options that target the genetic cause of the disease's growth. The drug works by inhibiting RAS proteins, which are involved in tumor development. It is administered as a daily pill and is specifically aimed at patients who have previously undergone treatment or cannot tolerate multi-drug chemotherapy. Clinical trials have shown that the medication increases the average survival time to 13.2 months, compared to 6.7 months with standard treatment. Although this is a significant step, the therapy does not cure the disease but aims to control it and extend survival.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)